# Study to Evaluate the Bioequivalence of Astellas Phama Korea Inc. "Harnal-D" in Healthy Volunteers

> **NCT03887858** · PHASE1 · COMPLETED · sponsor: **Chong Kun Dang Pharmaceutical** · enrollment: 30 (actual)

## Conditions studied

- Benign Prostatic Hyperplasia

## Interventions

- **DRUG:** Harnal-D Tab.
- **DRUG:** Chong Kun Dang Tamsulosin HCl Tab.

## Key facts

- **NCT ID:** NCT03887858
- **Lead sponsor:** Chong Kun Dang Pharmaceutical
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-03-11
- **Primary completion:** 2019-03-22
- **Final completion:** 2019-05-07
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2020-01-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03887858

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03887858, "Study to Evaluate the Bioequivalence of Astellas Phama Korea Inc. "Harnal-D" in Healthy Volunteers". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03887858. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*